Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 491,728
  • Shares Outstanding, K 84,200
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 2.28
  • Price/Sales 1,210.88
  • Price/Cash Flow N/A
  • Price/Book 3.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.40 +6.11%
on 06/11/18
6.35 -9.76%
on 06/18/18
-0.10 (-1.72%)
since 05/22/18
3-Month
5.01 +14.37%
on 04/03/18
6.69 -14.35%
on 05/16/18
+0.31 (+5.72%)
since 03/22/18
52-Week
4.41 +29.93%
on 12/19/17
7.68 -25.39%
on 07/17/17
-0.66 (-10.33%)
since 06/22/17

Most Recent Stories

More News
Aurinia Announces Results of Annual General Meeting

Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the eight incumbent directors of the Company were elected at the Company's...

AUP.TO : 7.60 (-2.94%)
AUPH : 5.73 (-1.88%)
Today's Research Reports on Hemostemix, Cotinga Pharmaceuticals, Aurinia Pharmaceuticals and Baylin Technologies

NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register...

AUPH : 5.73 (-1.88%)
Today's Free Reports Concordia International, ProMetic Life Sciences, Aurinia Pharma, and Oncolytics Biotech

LONDON, UK / ACCESSWIRE / June 20, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International, ProMetic...

AUPH : 5.73 (-1.88%)
PFSCF : 0.4472 (+1.64%)
CXR.TO : 0.29 (-3.33%)
Factors of Influence in 2018, Key Indicators and Opportunity within Shinhan Financial Group, Aurinia Pharmaceuticals, Delphi Technologies, Green Plains Partners LP, Sprague Resources LP, and CRH -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shinhan Financial Group Co...

DLPH : 48.67 (-1.56%)
AUPH : 5.73 (-1.88%)
SHG : 39.73 (+0.68%)
SRLP : 23.90 (+0.21%)
GPP : 17.40 (+0.87%)
CRH : 36.41 (+1.11%)
Aurinia Reports First Quarter Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye expected to begin in June 2018

AUP.TO : 7.60 (-2.94%)
AUPH : 5.73 (-1.88%)
Aurinia Pharmaceuticals Recognizes World Lupus Day(TM)with Activities Focused on Raising Awareness of Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus Day(TM)...

AUP.TO : 7.60 (-2.94%)
AUPH : 5.73 (-1.88%)
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare...

AUP.TO : 7.60 (-2.94%)
AUPH : 5.73 (-1.88%)
Research Reports on Aurinia Pharma, Immunovaccine, IntelliPharmaCeutics International, and OrganiGram Holdings

LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Aurinia Pharmaceuticals, Immunovaccine,...

AUP.TO : 7.60 (-2.94%)
AUPH : 5.73 (-1.88%)
OGRMF : 4.3000 (-0.46%)
IPCI : 0.46 (-1.30%)
New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SINOPEC Shangai Petrochemical...

VRX.TO : 32.19 (-2.04%)
AUPH : 5.73 (-1.88%)
SHI : 62.08 (+0.84%)
KNOP : 21.75 (+1.16%)
VRX : 24.27 (-1.82%)
SMBC : 39.90 (+1.99%)
DCM : 25.60 (-1.35%)
Free Research Reports on These Biotech Stocks -- Omeros, Argos Therapeutics, Array BioPharma, and Aurinia Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on OMER, ARGS, ARRY, and AUPH which can be accessed for free by signing up to www.wallstequities.com/registration....

AUPH : 5.73 (-1.88%)
ARGS : 0.1888 (+7.89%)
ARRY : 19.37 (-0.92%)
OMER : 18.67 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.00
1st Resistance Point 5.87
Last Price 5.73
1st Support Level 5.64
2nd Support Level 5.54

See More

52-Week High 7.68
Fibonacci 61.8% 6.43
Fibonacci 50% 6.05
Last Price 5.73
Fibonacci 38.2% 5.66
52-Week Low 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar